<DOC>
	<DOCNO>NCT00536653</DOCNO>
	<brief_summary>The aim study determine long term effect two type hormonal treatment advanced prostate cancer ( LHRH agonists antiandrogen bicalutamide ) bone mineral density patient .</brief_summary>
	<brief_title>Changes Bone Mineral Density Fracture Risk Patients Receiving Androgen Deprivation Therapy Prostate Cancer</brief_title>
	<detailed_description>Androgen ablation mainstay treatment advanced prostate cancer . However , luteinizing hormone-releasing ( LHRH ) agonists associate accelerated bone loss , osteoporosis fracture . An alternative non steroidal antiandrogen , bicalutamide , act androgen receptor maintain serum testosterone level . Our aim ass effect two treatment bone mineral density ( BMD ) select group patient , base BMD presentation . All patient undergo peripheral bone densitometry forearm , use dual energy X-ray absorptiometry . Osteoporotic patient , high risk fracture , commence bicalutamide . Osteopenic normal BMD patient commence LHRH agonist . All osteopenic osteoporotic patient give calcium vitamin D supplementation.Patients undergo annual bone densitometry scan , see clinic every 3 month monitor well-being PSA level . Any patient fail respond escape treatment hormone monotherapy manage accord clinical situation either switch combination LHRH bicalutamide additional oestrogen therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients locally advanced prostate cancer immediate androgen deprivation indicate Previous systemic therapy prostate cancer Patients illness medication would affect bone mineral metabolism Severe hepatic renal insufficiency</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>bone density</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>androgen antagonist</keyword>
</DOC>